Relationship between the acquired multi-drug resistance of human large cell lung cancer cell line NCI-H460 by cisplatin selection and p53 mutation

Zhonghua Jiehe he Huxi Zazhi

Volumn 28, Issue 2, 2005, Pages 102-107

  Wang, Tao ^a   Xu, Jun ^a   Zhong, Nan Shan ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Drug therapy; Drug tolerance; Genes, p53; Lung neoplasms; NCI H460 cell line

Indexed keywords

CISPLATIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

ARTICLE; BIOSYNTHESIS; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; HUMAN; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; MULTIDRUG RESISTANCE; MUTATION; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, LARGE CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; P-GLYCOPROTEIN; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33751092828     PISSN: 10010939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Siddik ZH, Mims B, Lozano G, et al. Independent pathways of P53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res, 1998,58:698-703.
2. Masters JR, Osborne EJ, Walker MC, et al. Hypersensitivity of human testis-tumor cell lines to chemotherapeutic drugs. Int J Cancer, 1993,53:340-346.
3. Petty RD, Sutherland LA, Hunter EM, et al. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin, 1995, 10: 29-34.
4. Flens MJ, Scheffer GL, van der Valk P, et al. Identification of novel drug resistance-associated proteins by a panel of rat monoclonal antibodies. Int J Cancer, 1997, 73:249-257.
5. Ren ZP, Hedrum A, Ponten F, et al. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene, 1996, 12: 765-773.
6. Oie HK, Russell EK, Carney DN, et al. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl, 1996,24:24-31.
7. Nishio K, Nakamura T, Koh Y, et al. Drug resistance in lung cancer. Curr Opin Oncol, 1999,11: 109-115.
8. Ishii M, Iwahana M, Mitsui I, et al. Growth inhibitory effect of a new camptolhecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs, 2000,11; 358-362.
9. Snow K, Judd W. Characteristics of doxorubicin- and amsacrine-resistant human leukaemic T cell lines. Br J Cancer, 1991, 63: 17-28.
10. Kawasaki M, Nakanishi Y, Kuwano K, et al. The utility of p53 immunostaining of transbronchial biopsy specimens in advanced non-small-cell lung cancer. Clin Cancer Res, 1997,3:1195-1200.
11. Izquierdo MA, Shoemaker RH, Flens MJ, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer, 1996,65:230-237.
12. Volm M. Multidrug resistance and its reversal. Anticancer Res, 1998,18:2905-2917.